Subscribe - Individual

Subscribe - Biotech Premium (Corporate)

Categories

Categories

CUV1
December 23rd, 2025

Bioshares Top 6 Picks for 2026: Clinuvel Pharmaceuticals - First Phase III Trial Readout in Vitiligo

Read More
SNT1
December 23rd, 2025

Top 6 Pick: Syntara - 5 Clinical Study Readouts in 2026

Read More
December 23rd, 2025

Top 6 Picks for 2026: Transformative Year Ahead for Cynata Therapeutics

Read More
CUV
December 16th, 2025

Clinuvel Pharmaceuticals to File ACTH Generic for Approval in 2026 for Billion Dollar Market

Read More
CC5
December 16th, 2025

Clever Culture Systems - Positioned for Strong Growth and Profitability

Read More
SNT2
December 16th, 2025

Syntara's Clever Phase Ib Skin Scarring Study in 2026 to Address 'Enormous' Market Opportunity

Read More
IMU
December 16th, 2025

Imugene Gets Clear Direction from FDA to Move into Pivotal Study

Read More
ACW
December 16th, 2025

Actinogen Medical - Good Rational for Positive Trial Outcome in 2026

Read More
CHM
November 21st, 2025

Chimeric Therapeutics - Stable Disease in Cohort 2

Read More
IMU2
November 21st, 2025

Imugene Prioritises Azer-Cel Program; Reduces Internal Drug Development

Read More

Pages



Quick Links

Contact Us

Address: 425 Smith St
Fitzroy Vic 3065
Phone: 0403 850 425
Email:editor@bioshares.com.au

Follow Us

Copyright © Bioshares
Site Map Privacy Search
Site by